Download PDF
Planta Med 2013; 79(01): 27-29
DOI: 10.1055/s-0032-1327925
Biological and Pharmacological Activity
Letters
Georg Thieme Verlag KG Stuttgart · New York

Topoisomerase I Inhibitor Evodiamine Acts As an Antibacterial Agent against Drug-Resistant Klebsiella pneumoniae

Jui-Yu Wu   *
1   College of Medicine, Taipei Medical University, Taipei, Taiwan
,
Ming-Chih Chang   *
2   Department of Dentistry, Cathay General Hospital, Taipei, Taiwan
,
Chien-Shu Chen
3   School of Pharmacy, China Medical University, Taichung, Taiwan
,
Hsiu-Chen Lin
4   Department of Laboratory Medicine, Taipei Medical University Hospital, Taipei, Taiwan
5   Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
,
Hsiang-Ping Tsai
1   College of Medicine, Taipei Medical University, Taipei, Taiwan
,
Chien-Chun Yang
1   College of Medicine, Taipei Medical University, Taipei, Taiwan
,
Che-Hsiung Yang
1   College of Medicine, Taipei Medical University, Taipei, Taiwan
,
Chun-Mao Lin
1   College of Medicine, Taipei Medical University, Taipei, Taiwan
6   Orthopedics Research Center, Taipei Medical University Hospital, Taipei, Taiwan
› Author Affiliations
Further Information

Publication History

received 14 June 2012
revised 04 October 2012

accepted 18 October 2012

Publication Date:
16 November 2012 (online)

   Permissions and Reprints

Abstract

Topoisomerase inhibitors have been developed in a variety of clinical applications. We investigated the inhibitory effect of evodiamine on E. coli topoisomerase I, which may lead to an anti-bacterial effect. Evodiamine inhibits the supercoiled plasmid DNA relaxation that is catalyzed by E. coli topoisomerase I, and computer-aided docking has shown that the Arg161 and Asp551 residues of topoisomerase I interact with evodiamine. We investigated the bactericidal effect of evodiamine against multidrug-resistant Klebsiella pneumoniae. Evodiamine showed a significantly lower minimal inhibitory concentration value (MIC 128 µg/mL) compared with antibiotics (> 512 µg/mL) against the clinical isolate of K. pneumoniae. The results suggested that evodiamine is a potential agent against drug-resistant bacteria.

Key words

antibiotic - drug resistance - evodiamine - K. pneumonia - zopoisomerase

* These authors contributed equally to this work.


 

  • References

  • 1 Rapp RP, Urban C. Klebsiella pneumoniae carbapenemases in Enterobacteriaceae: history, evolution, and microbiology concerns. Pharmacotherapy 2012; 32: 399-407
    CrossrefPubMedGoogle Scholar
  • 2 Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother 2009; 53: 2227-2238
    CrossrefPubMedGoogle Scholar
  • 3 Manageiro V, Ferreira E, Cougnoux A, Albuquerque L, Canica M, Bonnet R. Characterization of the inhibitor-resistant SHV beta-lactamase SHV-107 in a clinical Klebsiella pneumoniae strain coproducing GES-7 enzyme. Antimicrob Agents Chemother 2012; 56: 1042-1046
    CrossrefPubMedGoogle Scholar
  • 4 Walsh TR, Toleman MA, Jones RN. Comment on: Occurrence, prevalence and genetic environment of CTX-M beta-lactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother 2007; 59: 799-800 author reply 800–801
    CrossrefPubMedGoogle Scholar
  • 5 Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597-602
    CrossrefPubMedGoogle Scholar
  • 6 Teicher BA. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 2008; 75: 1262-1271
    CrossrefPubMedGoogle Scholar
  • 7 Wethington SL, Wright JD, Herzog TJ. Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. Expert Rev Anticancer Ther 2008; 8: 819-831
    CrossrefPubMedGoogle Scholar
  • 8 Masse E, Drolet M. Relaxation of transcription-induced negative supercoiling is an essential function of Escherichia coli DNA topoisomerase I. J Biol Chem 1999; 274: 16654-16658
    CrossrefPubMedGoogle Scholar
  • 9 Rui S, Tse-Dinh YC. Topoisomerase function during bacterial responses to environmental challenge. Front Biosci 2003; 8: d256-d263
    CrossrefPubMedGoogle Scholar
  • 10 Tse-Dinh YC. Bacterial topoisomerase I as a target for discovery of antibacterial compounds. Nucleic Acids Res 2009; 37: 731-737
    CrossrefPubMedGoogle Scholar
  • 11 Cheng B, Liu IF, Tse-Dinh YC. Compounds with antibacterial activity that enhance DNA cleavage by bacterial DNA topoisomerase I. J Antimicrob Chemother 2007; 59: 640-645
    CrossrefPubMedGoogle Scholar
  • 12 Jiang J, Hu C. Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa . Molecules 2009; 14: 1852-1859
    CrossrefPubMedGoogle Scholar
  • 13 Chan AL, Chang WS, Chen LM, Lee CM, Chen CE, Lin CM, Hwang J. Evodiamine stabilizes topoisomerase I-DNA cleavable complex to inhibit topoisomerase I activity. Molecules 2009; 14: 1342-1352
    CrossrefPubMedGoogle Scholar
  • 14 Pan X, Hartley JM, Hartley JA, White KN, Wang Z, Bligh SW. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells. Phytomedicine 2012; 19: 618-624
    CrossrefPubMedGoogle Scholar
  • 15 Bugreev DV, Nevinsky GA. Structure and mechanism of action of type IA DNA topoisomerases. Biochemistry (Mosc) 2009; 74: 1467-1481
    PubMedGoogle Scholar
  • 16 Zhu CX, Roche CJ, Papanicolaou N, DiPietrantonio A, Tse-Dinh YC. Site-directed mutagenesis of conserved aspartates, glutamates and arginines in the active site region of Escherichia coli DNA topoisomerase I. J Biol Chem 1998; 273: 8783-8789
    CrossrefPubMedGoogle Scholar
  • 17 Narula G, Annamalai T, Aedo S, Cheng B, Sorokin E, Wong A, Tse-Dinh YC. The strictly conserved Arg-321 residue in the active site of Escherichia coli topoisomerase I plays a critical role in DNA rejoining. J Biol Chem 2011; 286: 18673-18680
    CrossrefPubMedGoogle Scholar
  • 18 Lim KT, Yeo CC, Yasin RM, Balan G, Thong KL. Characterization of multidrug-resistant and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strains from Malaysian hospitals. J Med Microbiol 2009; 58: 1463-1469
    CrossrefPubMedGoogle Scholar
  • 19 Nazir H, Cao S, Hasan F, Hughes D. Can phylogenetic type predict resistance development?. J Antimicrob Chemother 2011; 66: 778-787
    CrossrefPubMedGoogle Scholar
  • 20 Rahman MM, Gray AI, Khondkar P, Islam MA. Antimicrobial activities of alkaloids and lignans from Zanthoxylum budrunga . Nat Prod Commun 2008; 3: 45-47
    PubMedGoogle Scholar
  • 21 Xu X, Leng F. A rapid procedure to purify Escherichia coli DNA topoisomerase I. Protein Expr Purif 2011; 77: 214-219
    CrossrefPubMedGoogle Scholar
  • 22 Feinberg H, Changela A, Mondragon A. Protein-nucleotide interactions in E. coli DNA topoisomerase I. Nat Struct Biol 1999; 6: 961-968
    CrossrefPubMedGoogle Scholar
  • 23 Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997; 267: 727-748
    CrossrefPubMedGoogle Scholar
  • 24 National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 6th edition, Vol. 23. Wayne: NCCLS Documents M7-A6; 2003
    Google Scholar
  • 25 Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res 1991; 19: 6823-6831
    CrossrefPubMedGoogle Scholar
  • 26 Fang H, Ataker F, Hedin G, Dornbusch K. Molecular epidemiology of extended-spectrum beta-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J Clin Microbiol 2008; 46: 707-712
    CrossrefPubMedGoogle Scholar